Emergent Biosolutions (NYSE:EBS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Monday.
According to Zacks, “Emergent surpassed both earnings and revenue estimates in the fourth-quarter of 2017. The company derives the majority of revenues from sales of BioThrax. Hence, its sole dependence on BioThrax for its revenues is concerning. Any hiccup in the production of BioThrax could severely hamper the company’s future growth prospects. Moreover, Emergent depends on certain single-source suppliers for key materials and services that are necessary for the manufacture of BioThrax which is also a matter of concern. Meanwhile, Emergent faces competition from a number of companies manufacturing Biodefense products. However, the company’s follow-on contract with the CDC and deals with the BARDA for BioThrax and NuThrax (next-generation anthrax vaccine) bode well for growth. Shares of the company have outperformed the broader industry in the last one year.”
EBS has been the subject of a number of other research reports. Goldman Sachs Group started coverage on shares of Emergent Biosolutions in a research report on Wednesday, January 24th. They set a “neutral” rating and a $55.00 price objective for the company. Chardan Capital upped their price objective on shares of Emergent Biosolutions from $47.00 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Emergent Biosolutions has a consensus rating of “Buy” and a consensus target price of $52.80.
Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported $0.74 EPS for the quarter, beating the Zacks’ consensus estimate of $0.70 by $0.04. The business had revenue of $193.80 million during the quarter, compared to analyst estimates of $189.96 million. Emergent Biosolutions had a net margin of 14.73% and a return on equity of 13.66%. The firm’s revenue for the quarter was up 27.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.74 earnings per share. sell-side analysts forecast that Emergent Biosolutions will post 2.24 EPS for the current fiscal year.
In related news, Director Zsolt Harsanyi sold 7,000 shares of the stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $42.47, for a total value of $297,290.00. Following the completion of the transaction, the director now owns 37,077 shares of the company’s stock, valued at $1,574,660.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jerome M. Hauer sold 5,152 shares of the stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $50.91, for a total transaction of $262,288.32. Following the completion of the transaction, the director now directly owns 23,797 shares of the company’s stock, valued at approximately $1,211,505.27. The disclosure for this sale can be found here. Insiders sold 77,739 shares of company stock valued at $3,595,013 in the last three months. Company insiders own 16.50% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. raised its position in Emergent Biosolutions by 23.2% in the second quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 587 shares in the last quarter. Financial Gravity Companies Inc. acquired a new position in Emergent Biosolutions in the fourth quarter worth about $118,000. First Quadrant L P CA acquired a new position in Emergent Biosolutions in the third quarter worth about $157,000. LS Investment Advisors LLC raised its position in Emergent Biosolutions by 183.0% in the fourth quarter. LS Investment Advisors LLC now owns 3,948 shares of the biopharmaceutical company’s stock worth $183,000 after purchasing an additional 2,553 shares in the last quarter. Finally, Victory Capital Management Inc. acquired a new position in Emergent Biosolutions in the third quarter worth about $191,000. 78.23% of the stock is owned by hedge funds and other institutional investors.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.